Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling

ABSTRACT Because of the recent awareness that vancomycin doses should aim to meet a target area under the concentration-time curve (AUC) instead of trough concentrations, more aggressive dosing regimens are warranted also in the pediatric population. In this study, both neonatal and pediatric pharmacokinetic models for vancomycin were externally evaluated and subsequently used to derive model-based dosing algorithms for neonates, infants, and children. For the external validation, predictions from previously published pharmacokinetic models were compared to new data. Simulations were performed in order to evaluate current dosing regimens and to propose a model-based dosing algorithm. The AUC/MIC over 24 h (AUC24/MIC) was evaluated for all investigated dosing schedules (target of >400), without any concentration exceeding 40 mg/liter. Both the neonatal and pediatric models of vancomycin performed well in the external data sets, resulting in concentrations that were predicted correctly and without bias. For neonates, a dosing algorithm based on body weight at birth and postnatal age is proposed, with daily doses divided over three to four doses. For infants aged <1 year, doses between 32 and 60 mg/kg/day over four doses are proposed, while above 1 year of age, 60 mg/kg/day seems appropriate. As the time to reach steady-state concentrations varies from 155 h in preterm infants to 36 h in children aged >1 year, an initial loading dose is proposed. Based on the externally validated neonatal and pediatric vancomycin models, novel dosing algorithms are proposed for neonates and children aged <1 year. For children aged 1 year and older, the currently advised maintenance dose of 60 mg/kg/day seems appropriate.

[1]  Johan W Mouton,et al.  Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. , 2015, The Journal of antimicrobial chemotherapy.

[2]  M. Papas,et al.  A Randomized Trial of Loading Vancomycin in the Emergency Department , 2015, The Annals of pharmacotherapy.

[3]  C. Knibbe,et al.  Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections , 2014, Expert review of anti-infective therapy.

[4]  K. V. Van Meurs,et al.  Association between Vancomycin Trough Concentration and Area under the Concentration-Time Curve in Neonates , 2014, Antimicrobial Agents and Chemotherapy.

[5]  A. Smits,et al.  Prospective validation of neonatal vancomycin dosing regimens is urgently needed , 2014, Current therapeutic research, clinical and experimental.

[6]  M. Danhof,et al.  Simultaneous Pharmacokinetic Modeling of Gentamicin, Tobramycin and Vancomycin Clearance from Neonates to Adults: Towards a Semi-physiological Function for Maturation in Glomerular Filtration , 2014, Pharmaceutical Research.

[7]  Yook-Hwan Noh,et al.  Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin‐resistant Staphylococcus aureus by modeling and simulation , 2014, Journal of clinical pharmacy and therapeutics.

[8]  A. Baruchel,et al.  Population Pharmacokinetics and Dosing Optimization of Vancomycin in Children with Malignant Hematological Disease , 2014, Antimicrobial Agents and Chemotherapy.

[9]  D. Tibboel,et al.  Evidence-Based Morphine Dosing for Postoperative Neonates and Infants , 2014, Clinical Pharmacokinetics.

[10]  D. Tibboel,et al.  Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling , 2013, Archives of Disease in Childhood.

[11]  M. Monuteaux,et al.  A Randomized Controlled Trial of a Vancomycin Loading Dose in Children , 2013, The Pediatric infectious disease journal.

[12]  B. Guglielmo,et al.  Desired Vancomycin Trough Serum Concentration for Treating Invasive Methicillin-resistant Staphylococcal Infections , 2013, The Pediatric infectious disease journal.

[13]  V. Biran,et al.  Amikacin Maturation Model as a Marker of Renal Maturation to Predict Glomerular Filtration Rate and Vancomycin Clearance in Neonates , 2013, Clinical Pharmacokinetics.

[14]  E. Capparelli,et al.  Improved Vancomycin Dosing in Children Using Area Under the Curve Exposure , 2013, The Pediatric infectious disease journal.

[15]  V. Biran,et al.  External Evaluation of Population Pharmacokinetic Models of Vancomycin in Neonates: The transferability of published models to different clinical settings. , 2013, British journal of clinical pharmacology.

[16]  A. Thomson,et al.  Continuous infusion of vancomycin in neonates , 2013, Archives of Disease in Childhood.

[17]  V. Biran,et al.  Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring , 2012, Archives of Disease in Childhood.

[18]  P. Ambrose,et al.  Evaluation of a pediatric continuous-infusion vancomycin therapy guideline. , 2012, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[19]  M. Danhof,et al.  Maturation of the Glomerular Filtration Rate in Neonates, as Reflected by Amikacin Clearance , 2012, Clinical Pharmacokinetics.

[20]  M. Danhof,et al.  Predictive Performance of a Busulfan Pharmacokinetic Model in Children and Young Adults , 2012, Therapeutic drug monitoring.

[21]  G. Giachetto,et al.  Vancomycin pharmacokinetic–pharmacodynamic parameters to optimize dosage administration in critically ill children , 2011, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[22]  Tsz-Yin So,et al.  An Evaluation of Initial Vancomycin Dosing in Infants, Children, and Adolescents , 2011, International journal of pediatrics.

[23]  L. Benet,et al.  Impact of a Hospitalwide Increase in Empiric Pediatric Vancomycin Dosing on Initial Trough Concentrations , 2011, Pharmacotherapy.

[24]  Meindert Danhof,et al.  Individualized dosing regimens in children based on population PKPD modelling: are we ready for it? , 2011, International journal of pharmaceutics.

[25]  Thomas M. English,et al.  Assessment of Vancomycin Dosing and Subsequent Serum Concentrations in Pediatric Patients , 2011, The Annals of pharmacotherapy.

[26]  C. Oudin,et al.  Vancomycin prescription in neonates and young infants: toward a simplified dosage , 2011, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[27]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  E. Hey Neonatal Formulary 6: Drug Use in Pregnancy and the First Year of Life , 2011 .

[29]  J. Peris,et al.  Population pharmacokinetic analysis of vancomycin in neonates. A new proposal of initial dosage guideline. , 2010, British journal of clinical pharmacology.

[30]  A. Martín-Suárez,et al.  Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation. , 2010, British journal of clinical pharmacology.

[31]  B. Charles,et al.  Population Pharmacokinetics of Vancomycin in Premature Malaysian Neonates: Identification of Predictors for Dosing Determination , 2010, Antimicrobial Agents and Chemotherapy.

[32]  M. Danhof,et al.  The role of population PK–PD modelling in paediatric clinical research , 2010, European Journal of Clinical Pharmacology.

[33]  L. Benet,et al.  Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation. , 2010, Clinical therapeutics.

[34]  L. Benet,et al.  Current Recommended Dosing of Vancomycin for Children With Invasive Methicillin-Resistant Staphylococcus aureus Infections Is Inadequate , 2009, The Pediatric infectious disease journal.

[35]  Meindert Danhof,et al.  Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling. , 2009, Drug discovery today.

[36]  M. Coulthard,et al.  Human renal function maturation: a quantitative description using weight and postmenstrual age , 2009, Pediatric Nephrology.

[37]  France Mentré,et al.  Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R , 2008, Comput. Methods Programs Biomed..

[38]  É. Barbotte,et al.  Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule , 2008, Archives of Disease in Childhood Fetal and Neonatal Edition.

[39]  F. de Zegher,et al.  Renal Drug Clearance in Preterm Neonates: Relation to Prenatal Growth , 2007, Therapeutic drug monitoring.

[40]  S. Zinner,et al.  Concentration-response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model. , 2007, International journal of antimicrobial agents.

[41]  V. Fanos,et al.  Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety , 2006, Expert opinion on drug safety.

[42]  France Mentré,et al.  Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide , 2006, Pharmaceutical Research.

[43]  L. Weisman,et al.  Coagulase-negative staphylococcal infections in the neonate and child: an update. , 2006, Seminars in pediatric infectious diseases.

[44]  G. Koren,et al.  Ontogeny of drug elimination by the human kidney , 2006, Pediatric Nephrology.

[45]  E. Niclas Jonsson,et al.  Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming , 2004, Comput. Methods Programs Biomed..

[46]  J. N. van den Anker,et al.  Vancomycin: pharmacokinetics and administration regimens in neonates. , 2004, Clinical pharmacokinetics.

[47]  N. Matsuura,et al.  Population Pharmacokinetics of Arbekacin, Vancomycin, and Panipenem in Neonates , 2004, Antimicrobial Agents and Chemotherapy.

[48]  Susan M Abdel-Rahman,et al.  Developmental pharmacology--drug disposition, action, and therapy in infants and children. , 2003, The New England journal of medicine.

[49]  W. Craig Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. , 2003, Infectious disease clinics of North America.

[50]  J. Connor,et al.  The Influences of Renal Function and Maturation on Vancomycin Elimination in Newborns and Infants , 2001, Journal of clinical pharmacology.

[51]  R. Schoemaker,et al.  Vancomycin population pharmacokinetics in neonates , 2000, Clinical pharmacology and therapeutics.

[52]  D. Lebel,et al.  A Population Pharmacokinetic Model for Vancomycin in Pediatric Patients and Its Predictive Value in a Naive Population , 2000, Antimicrobial Agents and Chemotherapy.

[53]  A. Thomson,et al.  Pharmacokinetics and dose requirements of vancomycin in neonates , 1999, Archives of disease in childhood. Fetal and neonatal edition.

[54]  T. Iga,et al.  Population pharmacokinetics of vancomycin in Japanese pediatric patients. , 1998, Therapeutic drug monitoring.

[55]  J. Rozé,et al.  Constant rate infusion of vancomycin in premature neonates: a new dosage schedule. , 1998, British journal of clinical pharmacology.

[56]  R. Schoemaker,et al.  Tobramycin population pharmacokinetics in neonates * , 1997 .

[57]  R. Brundage,et al.  Population pharmacokinetics of vancomycin in neonates , 1994, Clinical pharmacology and therapeutics.

[58]  G. Koren,et al.  Vancomycin pharmacokinetics and dose recommendations for preterm infants , 1987, Antimicrobial Agents and Chemotherapy.

[59]  M. Danhof,et al.  A Neonatal Amikacin Covariate Model Can Be Used to Predict Ontogeny of Other Drugs Eliminated Through Glomerular Filtration in Neonates , 2013, Pharmaceutical Research.

[60]  Evelina Tacconelli,et al.  Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. , 2012, The Journal of antimicrobial chemotherapy.

[61]  D. Levine,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[62]  N. Holford,et al.  Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. , 2007, British journal of clinical pharmacology.

[63]  M. Rybak,et al.  The pharmacokinetic and pharmacodynamic properties of vancomycin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[64]  Jerome J. Schentag,et al.  Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections , 2004, Clinical pharmacokinetics.

[65]  Jane Alcorn,et al.  Ontogeny of Hepatic and Renal Systemic Clearance Pathways in Infants Part I , 2002, Clinical pharmacokinetics.

[66]  Jane Alcorn,et al.  Ontogeny of Hepatic and Renal Systemic Clearance Pathways in Infants: Part II , 2002, Clinical pharmacokinetics.